Patient Perspectives on Treatment Options for Older Women With Hormone Receptor–Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.17129
Abstract: Key Points Question What are older women’s perspectives on recommendations for treatment de-escalation for low-risk, early-stage hormone receptor–positive breast cancer? Findings In this qualitative study of 30 participants aged 70 years or older, women expressed… read more here.
Keywords: hormone receptor; receptor positive; treatment; positive breast ... See more keywords
Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.1785
Abstract: Key Points Question Is neoadjuvant endocrine therapy (NET) an alternative treatment for neoadjuvant chemotherapy (NACT) in patients with invasive ductal carcinoma (IDC) of the breast who have strong hormone receptor (HR) positivity and human epidermal… read more here.
Keywords: endocrine therapy; hormone receptor; invasive ductal; ductal carcinoma ... See more keywords
Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.45934
Abstract: Key Points Question Is delayed adjuvant hormone therapy (AHT) associated with reduced survival in patients with hormone receptor–positive breast cancer? Findings In this cohort study of 144 103 US patients with hormone receptor–positive/human epidermal growth factor… read more here.
Keywords: survival; receptor positive; hormone receptor; breast cancer ... See more keywords
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3092
Abstract: The PIKTAM study evaluated the efficacy and safety of the PI3K inhibitor buparlisib in combination with tamoxifen in hormone receptor‐positive (HR+), HER2‐negative advanced breast cancer patients after failure of prior endocrine therapy. In this open‐label,… read more here.
Keywords: hormone receptor; positive her2; receptor positive; buparlisib combination ... See more keywords
Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5369
Abstract: We analyzed the effect of statins in patients with hormone receptor‐positive (HR+) metastatic breast cancer treated with everolimus + exemestane (EverX). read more here.
Keywords: receptor positive; hormone receptor; positive metastatic; metastatic breast ... See more keywords
Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early‐stage hormone‐receptor‐positive breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5488
Abstract: Guidelines allow for the omission of radiotherapy in older women with early‐stage, hormone‐receptor‐positive breast cancer, given that the patients receive adequate endocrine therapy (ET). However, the initiation of ET and survival outcomes after forgoing radiation… read more here.
Keywords: stage hormone; early stage; receptor positive; hormone receptor ... See more keywords
Chemogenomic Active Learning's Domain of Applicability on Small, Sparse qHTS Matrices: A Study Using Cytochrome P450 and Nuclear Hormone Receptor Families
Sign Up to like & getrecommendations! Published in 2018 at "ChemMedChem"
DOI: 10.1002/cmdc.201700677
Abstract: Computational models for predicting the activity of small molecules against targets are now routinely developed and used in academia and industry, partially due to public bioactivity databases. While models based on bigger datasets are the… read more here.
Keywords: active learning; hormone receptor; nuclear hormone; cytochrome p450 ... See more keywords
A nomogram for predicting axillary pathologic complete response in hormone receptor–positive breast cancer with cytologically proven axillary lymph node metastases
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.32830
Abstract: The objective of this study was to determine an axillary pathologic complete response (pCR) and its influencing factors in patients with hormone receptor (HR)–positive breast cancer and cytologically proven axillary lymph node metastases. A prediction… read more here.
Keywords: axillary pathologic; hormone receptor; receptor positive; pathologic complete ... See more keywords
Cost‐effectiveness of Choosing Wisely guidelines for axillary observation in women older than age 70 years with hormone receptor–positive, clinically node‐negative, operable breast tumors
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34207
Abstract: The Society for Surgical Oncology's Choosing Wisely guidelines recommend against sentinel lymph node biopsy (SLNB) in favor of observation in this population. Recent analyses reveal that this has not been widely adopted. The purpose of… read more here.
Keywords: receptor positive; hormone receptor; wisely guidelines; choosing wisely ... See more keywords
Divergent breast cancer incidence trends by hormone receptor status in the state of Sarawak, Malaysia
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32812
Abstract: Recent studies from high‐risk countries such as the US, Denmark and Ireland have shown rising incidence rates of hormone receptor (HR)‐positive and falling rates of HR‐negative breast cancers (BC). However, it remains unclear whether a… read more here.
Keywords: incidence; risk; hormone receptor; breast ... See more keywords
Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34487
Abstract: Per- and polyfluoroalkyl substances (PFAS) are highly persistent endocrine-disrupting chemicals that may contribute to breast cancer development; however, epidemiologic evidence is limited. We investigated associations between prediagnostic serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate… read more here.
Keywords: hormone receptor; status; breast cancer; receptor ... See more keywords